Page last updated: 2024-11-05

toliprolol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Toliprolol is a non-selective beta blocker used to treat hypertension and angina pectoris. Its synthesis involves the coupling of a 2-hydroxy-3-phenoxypropionic acid derivative with a 4-isopropylaminophenol derivative. It acts by blocking the beta-adrenergic receptors in the heart, leading to a decrease in heart rate and blood pressure. This compound is often studied for its potential therapeutic uses in treating cardiovascular diseases, as well as for its possible role in managing other conditions like migraine headaches. Toliprolol is relatively safe and well-tolerated, although it can cause side effects like fatigue, dizziness, and bradycardia.'

toliprolol: was MH 1975-92 (see under PROPANOLAMINES 1981-90, was DOBEROL see under PROPANOLAMINES 1975-80); KOE 592 was see TOLIPROLOL 1975-92; use PROPANOLAMINES to search TOLIPROLOL 1975-92; beta adrenergic blockader with some stimulant action; it has been proposed for angina pectoris [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID18047
CHEMBL ID67096
CHEBI ID134918
SCHEMBL ID79267
MeSH IDM0198309

Synonyms (41)

Synonym
2-propanol, 1-[(1-methylethyl)amino]-3-(3-methylphenoxy)-
toliprolol
toliprolol [inn]
1-(isopropylamino)-3-(m-tolyloxy)-2-propanol
brn 1874722
einecs 220-905-6
2-propanol, 1-((1-methylethyl)amino)-3-(3-methylphenoxy)-
toliprololum [inn-latin]
isopropylamino-1-m-tolyloxy-3-propan-2-ol [german]
mhip
2-propanol, 1-(isopropylamino)-3-(m-tolyloxy)-
CHEBI:134918
ko 592 [as hydrochloride]
ici 45763 [as hydrochloride]
CHEMBL67096
1-(3-methylphenoxy)-3-(propan-2-ylamino)propan-2-ol
2933-94-0
unii-dcp58j201d
toliprololum
isopropylamino-1-m-tolyloxy-3-propan-2-ol
dcp58j201d ,
AKOS008962502
ici-45763 free base
toliprolol [mi]
1-(3-methylphenoxy)-3-(isopropylamino)-2-propanol
ko-592 free base
1-(3-methylphenoxy)-2-hydroxy-3-isopropylaminopropane
1-((1-methylethyl)amino)-3-(3-methylphenoxy)-2-propanol
(+/-)-1-(isopropylamino)-3-(m-tolyloxy)-2-propanol
SCHEMBL79267
1-(3'-methyl-phenoxy)-3-(iso-propylamino)-2-propanol
1-(3'-methylphenoxy)-3-(iso-propylamino)-2-propanol
ici-45763 (salt/mix)
ko 592 (salt/mix)
1-(isopropylamino)-3-(3-methylphenoxy)-2-propanol #
SR-01000945167-2
sr-01000945167
Q15633990
1-(3-methylphenoxy)-3-[(propan-2-yl)amino]propan-2-ol
EN300-147616
DTXSID50863061
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-2 adrenergic receptor Bos taurus (cattle)Kd0.04370.00061.47759.1200AID40694
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (7)

Processvia Protein(s)Taxonomy
receptor-mediated endocytosisBeta-2 adrenergic receptor Bos taurus (cattle)
regulation of smooth muscle contractionBeta-2 adrenergic receptor Bos taurus (cattle)
positive regulation of MAPK cascadeBeta-2 adrenergic receptor Bos taurus (cattle)
negative regulation of G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptor Bos taurus (cattle)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-2 adrenergic receptor Bos taurus (cattle)
positive regulation of autophagosome maturationBeta-2 adrenergic receptor Bos taurus (cattle)
positive regulation of lipophagyBeta-2 adrenergic receptor Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
beta2-adrenergic receptor activityBeta-2 adrenergic receptor Bos taurus (cattle)
protein homodimerization activityBeta-2 adrenergic receptor Bos taurus (cattle)
norepinephrine bindingBeta-2 adrenergic receptor Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
early endosomeBeta-2 adrenergic receptor Bos taurus (cattle)
Golgi apparatusBeta-2 adrenergic receptor Bos taurus (cattle)
receptor complexBeta-2 adrenergic receptor Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID218845Change in Gibb's free energy at Low affinity beta-2-adrenoceptor in the membranes of bovine skeletal muscle preparation1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Mapping of the beta 2-adrenoceptor on Chang liver cells. Differences between high- and low-affinity receptor states.
AID40694Affinity for cow beta-2 adrenergic receptor by measuring displacement (-)-[3H]dihydroalprenolol (DHA)1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Quantitative evaluation of the beta 2-adrenoceptor affinity of phenoxypropanolamines and phenylethanolamines.
AID42208Beta-1 adrenergic receptor activation measured by isoprenaline-induced positive inotropic effect in guinea pig left atrium1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Synthesis and beta-adrenergic antagonism of 2-(aryloxy)-1-(2-piperidyl)ethanols.
AID40686Affinity for cow beta-2 adrenergic receptor by measuring displacement (-)-[3H]dihydroalprenolol (DHA)1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Quantitative evaluation of the beta 2-adrenoceptor affinity of phenoxypropanolamines and phenylethanolamines.
AID218848Change in Gibb's free energy at Low affinity beta-2-adrenoceptor in the Chang living cells1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Mapping of the beta 2-adrenoceptor on Chang liver cells. Differences between high- and low-affinity receptor states.
AID603953In-vivo plasma to lung partition coefficients of the compound, logP(lung) in rat2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
AID229400Selectivity of inhibition at beta-1 versus beta-2 adrenergic receptors, ratio of pA2 values1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Synthesis and beta-adrenergic antagonism of 2-(aryloxy)-1-(2-piperidyl)ethanols.
AID79324Antagonism of isoprenaline-induced relaxation of guinea pig tracheal chains, contracted with carbachol1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Synthesis and beta-adrenergic antagonism of 2-(aryloxy)-1-(2-piperidyl)ethanols.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (37.50)18.7374
1990's0 (0.00)18.2507
2000's3 (37.50)29.6817
2010's0 (0.00)24.3611
2020's2 (25.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.42

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.42 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.14 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.42)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (12.50%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]